ICU Trials by ClinCalc
source

ICU Trials by ClinCalc

(157)
Price
5,61 €
Category
Medical
Last update
Dec 01, 2021
Publisher
ClinCalc LLC Contact publisher
Loading...

Ratings & Reviews performance

Ratings & Reviews performance provides an overview of what users think of your app. Here are the key metrics to help you identify how your app is rated by users and how successful is your review management strategy.

Number of reviews,
total
157
Avg rating,
total
⭐4.6
Loading...

Description

1404 chars

ICU Trials is a quick pocket reference for both the novice and seasoned critical care clinician. This app does not replace the original manuscript of these landmark critical care trials – instead, it serves as a fast reference and learning tool for some of the most important ICU trials over a wide range of specialties. Each entry contains a short one-liner about the critical care trial and key points, which includes only the most pertinent details, such as inclusion/exclusion criteria, treatment protocols, pertinent endpoints and findings, as well as expert commentary regarding key subgroup analyses or limitations to the trial. Want to send a colleague a citation? Use the "Share Trial" button to send a PubMed link via email. Using this feature, it’s incredibly easy to share pivotal critical care trials with students, residents, and other colleagues. The database features 83 landmark trials related to: ARDS, cardiac arrest, DVT/PE, delirium, glycemic control, heart failure, hemorrhage, meningitis, nephroprotection, nutrition, pneumonia, sedation, seizure, sepsis/shock, spinal cord injury, stroke, and subarachnoid hemorrhage – with more trials and topics to be added on a regular basis! This app is designed and maintained by Sean P. Kane, PharmD, BCPS -- a clinical pharmacist specializing in critical care with a background in information technology and application development.

Screenshots

https://play-lh.googleusercontent.com/J16k-VaRVnDJCT5Z6hxyJSBvQABG9GhhNNRMtweND09Q3JNedADImANDp9VoKxHKHQ0=w720-h310https://play-lh.googleusercontent.com/agAOg9ZHymXZgnv-aoRAP5TGK-SZ_y0WDDFwipSoHeHPnvZ9WKWo_wHifyAO1Iyx3Bpj=w720-h310https://play-lh.googleusercontent.com/7dKUpPWPHlkHBwfVFW6aCrs9lmt7nnp6RkLNLlggRWLvkrmbVL5iQiv0edxxOQrfDA=w720-h310https://play-lh.googleusercontent.com/151HwKMpfNWjO9K4X6rVSkysd_p0AQxqRs5qWPFa3YL_R3tdJw-UQwsjyPrc0loyEmo=w720-h310https://play-lh.googleusercontent.com/GRhv_4UYZfp-8eis_OuD3j6YJLUOz3I1bExe_Tol_KWkACzNXRxBHPwPvNlN3LWpskM=w720-h310https://play-lh.googleusercontent.com/7ScYflctYsZzqvwHsaxMLK7BQlQRdHiXVilUuiVOjYb4-z_UwCRF2Jxghcbr89foh2Rl=w720-h310https://play-lh.googleusercontent.com/2Uk5RBK92p2Ipok2Si_R5iPWmCaaagsi92Fyy97vgnnpw_a7KjiN__qZPNQZuX5CFrQ=w720-h310
Loading...
Loading...

Find growth insights on our blog

React to user feedback and market trends faster